Objetivo
This icovid project is the continuation of the pro bono icovid initiative that developed the CE-marked and FDA permitted AI-based CT analysis software, icolung, and made it available in over 65 hospitals worldwide. The icovid project aims to improve the software making it of greater value as the clinical needs evolve, validating it in renowned academic centers and deploying it at large-scale across Europe. icolung is expected to have a significant societal impact by increasing confidence when making a CT diagnosis and providing accurate quantification of disease and prognostic information in patients with suspected COVID-19 disease. Importantly, even in a low prevalence setting icolung may have a much higher sensitivity and a comparable specificity for the diagnosis compared to the RT-PCR testing used currently. Identifying infected patients earlier will reduce the risk of further contamination and allows the right patient management to start earlier. icolung also predicts the risk of developing severe COVID-19 disease for which ICU admission and mechanical ventilation are required, allowing optimization of patient care. This project will significantly strengthen the position of two European SMEs in the rapidly growing market of AI in healthcare. One of them is coordinating the project and the consortium involved, enabling quick responses in a rapidly changing environment. The consortium builds further on existing organic collaboration and contains world-renowned experts of which multiple are part of the Executive Committee of the European Society of Thoracic Imaging.
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
H2020-SC1-PHE-CORONAVIRUS-2020-2
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-PHE-CORONAVIRUS-2020-2-CNECT
Régimen de financiación
IA - Innovation actionCoordinador
3012 Leuven
Bélgica
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.